{"entity":{"id":"nct02498613","kind":"trial","name":"Cediranib plus olaparib in advanced solid tumors","aka":["A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors"],"tldr":"This study tests cediranib with olaparib in selected advanced cancers, including triple-negative breast cancer. It asks whether the combination can shrink tumors; it is not a study of treatment after curative breast surgery.","summary":"This study tests cediranib with olaparib in selected advanced cancers, including triple-negative breast cancer. It asks whether the combination can shrink tumors; it is not a study of treatment after curative breast surgery.\n\nInterventional study registered as NCT02498613, sponsored by National Cancer Institute (NCI). Registry phase: 2. Registry enrollment is 122 participants (actual). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"active","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT02498613","url":"https://clinicaltrials.gov/study/NCT02498613"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT02498613"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["olaparib"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02498613","phase":"2","setting":"Selected advanced solid tumors, including triple-negative breast cancer","sponsor":"National Cancer Institute (NCI)","participation":[{"nct":"NCT02498613","source":"https://clinicaltrials.gov/study/NCT02498613","fetchedAt":"2026-10-10T20:54:20.834374Z","studySha256":"5ad4fbd3a1f5d117d04b5cbe16795ff53f68c2053378e4eea8683742b4b9c468","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-25","leadSponsor":"National Cancer Institute (NCI)","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":122,"enrolmentType":"ACTUAL","siteCount":16,"recruitingSiteCount":0,"countries":["Canada","United States"]}],"started":"2016-08-31","startedType":"actual","enrolled":122,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02498613/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}